New Investment Opportunity: Genopore
Early disease detection through proteomics
- First large-scale, low-cost, single-molecule protein sequencing and identification system aims to enable early detection of cancer and other diseases
- Seed-stage, pre-revenue startup pioneering revolutionary proteomic technology developed over decades of research at Harvard, Boston U and Technion-Israel Institute of Technology's Meller Lab
- Liquid biopsy detection of cancer from blood sample instead of tissue is fast-growing market: Oxford Nanopore, similar technology for DNA and RNA, has $4.4B valuation
- World-class team of academic and industry veterans led by Prof. Amit Meller with backgrounds in biophysics, semiconductors, and systems, combining leading-edge technology with industry expertise
- $4M Seed round
Dear Josb,
Proteomics, the extensive study of proteins, is the next big transformation in life sciences. Proteins provide more information than genetics because they are impacted by both genetics and environmental factors. The ability to analyze single molecules in a sample can drive significant improvements in capabilities in the early detection of cancer and other diseases, as well as a wide range of sectors, but is technically very challenging to achieve.
OurCrowd is investing in Genopore, an Israeli seed-stage, pre-revenue startup developing technology to take proteomics to a new level. The details in this email are based on information received from, and verified solely by, the company.
The Solution
Genopore plans to be the first company to deliver a revolutionary, true single-molecule, cost-effective, highly accurate, highly sensitive, and high-throughput whole-protein identification system using chip-based technology. This capability will enable the early detection of cancer and other diseases.
Genopore expects its technology to find applications in drug discovery, clinical applications, the food industry, agriculture, and research and academia.
Genopore is tying together advances in biochemistry, semiconductors, photonics, and artificial intelligence/machine learning. The company's core optical nanopore sensor technology, Opti-Pore, was developed by co-founder Professor Amit Meller, a world-renowned scientist, while working at the Technion-Israel Institute of Technology, Harvard, and Boston University.
The Sector
Liquid biopsy - the detection of cancer from blood samples instead of tissues - is a rapidly growing market. Oxford Nanopore, a company using similar technology to analyze DNA and RNA, has a $4.4B valuation.
The Team
Genopore's world-class team brings together academic and industry veterans. In addition to Professor Meller, the team includes executives with backgrounds in biophysics, semiconductors, and systems, combining leading-edge technology experience with industry expertise. CEO David Baum is a serial entrepreneur who has founded leading semiconductor companies that reached hundreds of millions of dollars in sales.
This Round
Proceeds from this $4M Seed round will be used to develop the complete system, based on the core patented technology that Dr. Meller has been working on for years.
Meet the CEO
We're hosting a webinar on Thursday, February 24th, at 7PM Israel / 12PM New York / 9AM San Francisco for investors to meet CEO David (Dudi) Baum, and learn more about Genopore.
Can't make the webinar? Register and we will send you a recording of the call.
The Genopore Solution
Genopore is developing an end-to-end solution comprised of a system, consumables and reagents, data analytics, and bioinformatics capabilities. The Genopore platform will be high performance with high sensitivity, high throughput, and a high dynamic range. It will have single-molecule resolution to cover 99% of the human proteome, from single cells, and it will be cost-effective. Genopore's technology enables a small form-factor product for field applications in various industries, without requiring trained technicians.
Next steps:
Photo Credit: http://www.meller-lab.net
0 Comments